CD3xBCMA-bsAb (Protheragen)

N/A

Report date: 2026/03/24 20:00:35

Base Information

Drug NameCD3xBCMA-bsAb (Protheragen)
Drug Alias Nameanti-CD3/anti-BCMA bispecific T-cell engager (Protheragen)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionCD3 T-cell engagersAnti-BCMA
TargetsT cell surface glycoprotein CD3B-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesProtheragen Inc
China Registration ClassN/A

Develop Information

Active CompaniesProtheragen Inc
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A